{"filing":{"accession_number":"0001193125-26-405776","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"d178892d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/d178892d8k.htm"},"events":[{"id":35551,"run_id":32748,"accession_number":"0001193125-26-405776","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.93,"summary":"Summit Therapeutics entered into a securities purchase agreement with AstraZeneca for a $2.0 billion private placement of 108,955.3686 shares of Class A Convertible Preferred Stock, convertible into common stock at a 1:1,000 ratio ($18.36 per share equivalent). The unregistered securities were issued under Section 4(a)(2) and Regulation D exemptions, with Summit agreeing to file a registration statement for resale of the underlying common shares.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39635,"accession_number":"0001193125-26-405776","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Summit Therapeutics entered into a securities purchase agreement with AstraZeneca to issue 108,955.3686 shares of Class A Convertible Preferred Stock for $2.0 billion in gross proceeds. The preferred shares are convertible into common stock at a 1:1,000 ratio, representing a significant dilutive equity issuance. While the filing also mentions clinical collaboration agreements, the Item 1.01 disclosure centers on the material definitive agreement for the equity investment—a private placement of convertible preferred shares issued in reliance on Section 4(a)(2) and Regulation D exemptions from registration.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:06:40.059935+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39636,"accession_number":"0001193125-26-405776","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Summit Therapeutics has entered into an unregistered sale of convertible preferred shares to AstraZeneca for $2.0 billion, convertible into common stock at a 1:1,000 ratio representing $18.36 per share. The filing explicitly states the securities \"have not been registered under the Securities Act of 1933\" and references Item 3.02 (Unregistered Sales of Equity Securities), which is the standard disclosure vehicle for dilutive equity issuances. This is a material capital raise that will significantly dilute existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:06:40.059935+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39637,"accession_number":"0001193125-26-405776","item_number":"5.03","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Summit filed a Certificate of Designation authorizing 108,956 shares of Class A Convertible Preferred Stock in connection with a $2 billion private placement by AstraZeneca. The preferred shares are convertible into common stock at a 1:1,000 ratio, representing a significant dilutive issuance of unregistered equity securities. This is a material capital-raising transaction that will substantially dilute existing shareholders upon conversion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:06:40.059935+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39638,"accession_number":"0001193125-26-405776","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Summit announced a $2 billion strategic equity investment by AstraZeneca in convertible preferred shares (approximately 108,955 shares convertible at a 1:1,000 ratio into common stock). The press release explicitly states the securities \"have not been registered under the Securities Act of 1933\" and notes that Summit \"has agreed to file a registration statement with the Securities and Exchange Commission (SEC) registering the resale of the shares of common stock following the closing.\" This is a material unregistered private placement of equity securities at $18.36 per share equivalent, representing a significant dilutive capital raise typical of Item 3.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:06:40.059935+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39635,"accession_number":"0001193125-26-405776","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Summit Therapeutics entered into a securities purchase agreement with AstraZeneca to issue 108,955.3686 shares of Class A Convertible Preferred Stock for $2.0 billion in gross proceeds. The preferred shares are convertible into common stock at a 1:1,000 ratio, representing a significant dilutive equity issuance. While the filing also mentions clinical collaboration agreements, the Item 1.01 disclosure centers on the material definitive agreement for the equity investment—a private placement of convertible preferred shares issued in reliance on Section 4(a)(2) and Regulation D exemptions from registration.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:06:40.059935+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-28"},{"id":39636,"accession_number":"0001193125-26-405776","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Summit Therapeutics has entered into an unregistered sale of convertible preferred shares to AstraZeneca for $2.0 billion, convertible into common stock at a 1:1,000 ratio representing $18.36 per share. The filing explicitly states the securities \"have not been registered under the Securities Act of 1933\" and references Item 3.02 (Unregistered Sales of Equity Securities), which is the standard disclosure vehicle for dilutive equity issuances. This is a material capital raise that will significantly dilute existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:06:40.059935+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-28"},{"id":39637,"accession_number":"0001193125-26-405776","item_number":"5.03","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Summit filed a Certificate of Designation authorizing 108,956 shares of Class A Convertible Preferred Stock in connection with a $2 billion private placement by AstraZeneca. The preferred shares are convertible into common stock at a 1:1,000 ratio, representing a significant dilutive issuance of unregistered equity securities. This is a material capital-raising transaction that will substantially dilute existing shareholders upon conversion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:06:40.059935+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-28"},{"id":39638,"accession_number":"0001193125-26-405776","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Summit announced a $2 billion strategic equity investment by AstraZeneca in convertible preferred shares (approximately 108,955 shares convertible at a 1:1,000 ratio into common stock). The press release explicitly states the securities \"have not been registered under the Securities Act of 1933\" and notes that Summit \"has agreed to file a registration statement with the Securities and Exchange Commission (SEC) registering the resale of the shares of common stock following the closing.\" This is a material unregistered private placement of equity securities at $18.36 per share equivalent, representing a significant dilutive capital raise typical of Item 3.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:06:40.059935+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-28"}]}